莱茵生物
(002166)
| 流通市值：41.29亿 | | | 总市值：59.66亿 |
| 流通股本：5.14亿 | | | 总股本：7.42亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,169,965,060.76 | 725,488,517.4 | 341,215,308.03 | 1,493,929,546.69 |
| 营业收入 | 1,169,965,060.76 | 725,488,517.4 | 341,215,308.03 | 1,493,929,546.69 |
| 二、营业总成本 | 1,055,454,984.4 | 657,852,247.63 | 297,588,999.84 | 1,406,218,107.09 |
| 营业成本 | 840,516,661.85 | 518,022,016.19 | 252,322,968.66 | 1,129,187,821.45 |
| 税金及附加 | 3,171,474.18 | 2,562,550.64 | 580,949.35 | 10,442,792.9 |
| 销售费用 | 42,410,232.17 | 28,003,103.24 | 11,815,028.89 | 54,024,604.22 |
| 管理费用 | 97,158,131.75 | 62,780,148.91 | 19,750,550.19 | 139,748,302.56 |
| 研发费用 | 47,363,853.57 | 34,432,098.96 | 9,659,639.15 | 48,385,939.81 |
| 财务费用 | 24,834,630.88 | 12,052,329.69 | 3,459,863.6 | 24,428,646.15 |
| 其中:利息费用 | 30,930,108.73 | 19,362,059 | 7,525,723.28 | 32,901,228.59 |
| 其中:利息收入 | 2,920,421.73 | 1,992,883.07 | 982,276.49 | 7,894,233.33 |
| 加:公允价值变动收益 | -6,609,671.77 | -4,502,537.93 | -14,082,608.55 | 45,348,387.06 |
| 加:投资收益 | 7,179,333.59 | 7,362,916.12 | - | 4,827,738.46 |
| 资产处置收益 | 6,660.58 | -8,561 | - | -713,556.88 |
| 资产减值损失(新) | 672,135.1 | 223,159.57 | -19,840.06 | -44,290,289.27 |
| 信用减值损失(新) | 2,425,743.85 | 2,386,908.91 | 2,840,103.14 | 5,659,484.39 |
| 其他收益 | 15,938,390.85 | 13,843,320.84 | 6,330,600.6 | 19,778,163.88 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 134,122,668.56 | 86,941,476.28 | 38,694,563.32 | 118,321,367.24 |
| 加:营业外收入 | -8,195.79 | 811.59 | 810.89 | 227,862.65 |
| 减:营业外支出 | 6,371,083.91 | 5,474,267.46 | 1,107,283.01 | 2,186,646.53 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 127,743,388.86 | 81,468,020.41 | 37,588,091.2 | 116,362,583.36 |
| 减:所得税费用 | 21,727,600.37 | 13,472,528.13 | 9,703,544.43 | 18,016,580.9 |
| 六、净利润 | 106,015,788.49 | 67,995,492.28 | 27,884,546.77 | 98,346,002.46 |
| 持续经营净利润 | 106,015,788.49 | 67,995,492.28 | 27,884,546.77 | 98,346,002.46 |
| 归属于母公司股东的净利润 | 101,621,708.59 | 64,893,065.27 | 26,790,064.13 | 82,510,982.99 |
| 少数股东损益 | 4,394,079.9 | 3,102,427.01 | 1,094,482.64 | 15,835,019.47 |
| (一)基本每股收益 | 0.14 | 0.09 | 0.04 | 0.11 |
| (二)稀释每股收益 | 0.14 | 0.09 | 0.04 | 0.11 |
| 八、其他综合收益 | -2,080,182.64 | 3,673,546.89 | 1,454,414.23 | 14,162,932.96 |
| 归属于母公司股东的其他综合收益 | -2,080,182.64 | 3,673,546.89 | 1,454,414.23 | 14,162,932.96 |
| 九、综合收益总额 | 103,935,605.85 | 71,669,039.17 | 29,338,961 | 112,508,935.42 |
| 归属于母公司股东的综合收益总额 | 99,541,525.95 | 68,566,612.16 | 28,244,478.36 | 96,673,915.95 |
| 归属于少数股东的综合收益总额 | 4,394,079.9 | 3,102,427.01 | 1,094,482.64 | 15,835,019.47 |
| 公告日期 | 2024-10-31 | 2024-08-29 | 2024-04-27 | 2024-04-10 |
| 审计意见(境内) | | | | 标准无保留意见 |